THG
THG · Main Market · Personal Care, Drug and Grocery Stores · mcap £416m · 27.2p
THG owns online retail brands, mainly LOOKFANTASTIC and Cult Beauty in beauty and Myprotein in sports nutrition. It sells direct to consumers and, increasingly, through licensed products in shops.
| Date | Type | Announcement | Day |
|---|---|---|---|
| 10 Sep 26 | Results | Half-year Results
H1 2026 revenue grew 7.2% to £828.7m; Adjusted EBITDA more than doubled to £42.8m, ahead of guidance. |
−12.7% |
|
ahead of guidance expectations Group revenue £828.7m (£783.4m)Revenue growth (continuing CCY) +7.2% (+5.8% reported)Adjusted EBITDA £42.8m (£24.0m)Adjusted EBITDA growth (LFL) +109%Adjusted EBITDA margin 5.2% (3.1%)Myprotein branded products sold 58.5m (37.2m)
|
|||
| 09 Sep 26 | Notice of Interim Results
THG to publish interim results for six months ended 30 June 2026. |
−3.2% | |
| 07 Aug 26 | Capital Reduction Becomes Effective
High Court order confirms capital reduction through cancellation of share premium account and capital redemption reserve. |
−0.1% | |
| 28 Jul 26 | Outcome of Court Hearing on Reduction of Capital
High Court sanctions cancellation of share premium account and capital redemption reserve. |
−0.2% | |
| 24 Jun 26 | Trading update | AGM Trading Statement
H1 revenue growth of 6.5%, Adjusted EBITDA up 36% YoY, Term Loan B trading above par for first time. |
−1.9% |
|
in line expectations H1 revenue growth c.+6.5%H1 revenue growth excluding THG Nutrition Asia +7.6%LTM Adjusted EBITDA to May 2026 £94mLTM Adjusted EBITDA growth YoY +36%H1 Adjusted EBITDA at least £40mRetrospective VAT claims submitted c.£78m
|
|||
| 12 Jun 26 | €445m Term Loan B trading above par at record high
€445m Term Loan B debt security trading above par for first time since March 2025 issuance. |
+2.7% | |
|
Term Loan B €445mTLB price increase since 2 January 2026 500bpsYield reduction c.1.3%Outperformance vs European Leveraged Loan Index c.400bps
|
|||
| 21 Apr 26 | Trading update | Trading Statement
Q1 revenue grew 7.0% on constant currency basis, strongest since 2021, with Beauty and Nutrition both accelerating. |
+2.7% |
|
in line expectations Group revenue Q1 2026 £393.1m (£375.6m Q1 2025)Group revenue growth (constant currency) +7.0% (+0.9% Q4 2025)THG Beauty revenue £233.3m (£227.8m Q1 2025)THG Beauty growth (constant currency) +5.8% (+5.4% H2 2025)THG Nutrition revenue £159.8m (£147.8m Q1 2025)THG Nutrition growth (constant currency) +8.8% (+9.7% H2 2025)
|
|||
| 20 Apr 26 | Notice of Q1 Trading Update
THG to report Q1 2026 trading results on 21 April 2026. |
−1.5% | |
| 08 Apr 26 | Results | Annual Report & Accounts 2025
Annual Report & Accounts for 2025 published and made available to shareholders. |
+5.4% |
| 26 Mar 26 | Results | Preliminary FY 2025 results
FY 2025 revenue +2.3% CCY, Adjusted EBITDA £76.6m ahead of guidance, net debt reduced to £233m. |
+6.0% |
|
ahead expectations FY 2025 revenue £1,717.0m (£1,751.4m)Continuing CCY revenue growth +2.3%Adjusted EBITDA £76.6m (£83.3m)Operating profit £8.1m ((£147.9m) loss)Net debt £233.0m (£304.3m)Profit after tax £54.1m ((£326.1m) loss)
|
|||
| 12 Feb 26 | Myprotein licensing partnership with Greencore
Myprotein launches protein-rich convenience foods with Greencore, available in Sainsbury's stores. |
−1.1% | |
|
Myprotein licensed units sold in 2025 over 43 millionLicensed products target 2026 over 60 millionOffline doors expansion target 100,000
|
|||
| 22 Jan 26 | Application for Listing and Total Voting Rights
Application made for listing of 40.6m ordinary shares under Long Term Incentive Plan on LSE. |
+0.9% | |
| 16 Jan 26 | Change to Board Committee Membership
Milyae Park replaces Sue Farr as Chair of Sustainability Committee from 26 January 2026. |
−0.8% | |
| 13 Jan 26 | Trading update | Q4 2025 Trading Statement
Q4 2025 revenue grew 7.0%, outperforming guidance. H2 revenue was 14% ahead of guidance range. |
−8.9% |
|
14% ahead of H2 guidance range at top end expectations Q4 2025 Group revenue £527.4m (£507.6m)Q4 2025 YoY growth (CCY) +7.0% (+0.8%)H2 2025 YoY growth +6.7% (+3.9% to +5.9% guidance)FY 2025 revenue £1,716.0m (+2.3% YoY)THG Beauty Q4 growth (CCY) +6.4% (+0.8% FY2024)THG Nutrition Q4 growth (CCY) +8.5% (-9.4% FY2024)
|
|||
| 05 Dec 25 | Director Declaration
Independent Non-Executive Director Gillian Kent appointed as non-executive director of STV Group plc. |
+1.6% | |
| 05 Dec 25 | Admission of Convertible Loan Shares and TVR
209m convertible loan shares admitted to trading; total voting rights now 1.6bn. |
+1.6% | |
|
Convertible loan shares admitted 209,086,407Total voting rights post-admission 1,599,781,137
|
|||
| 26 Nov 25 | Director dealing | PDMR/PCA Shareholdings
Matthew Moulding transferred 181.8m shares between two of his controlled companies at 44p per share. |
+0.3% |
| 17 Nov 25 | Myprotein joins forces with Mars
Myprotein launches Snickers-flavoured protein products in partnership with Mars, expanding retail presence. |
−2.8% | |
|
Launch date 20 November 2025Retail doors target over 40,000 by end of 2025Units sales target 45 million globally by end of 2025UK protein market CAGR 7% between 2024-2029
|
|||
| 28 Oct 25 | Director Declaration
Non-Executive Director Gillian Kent appointed as non-executive director of Crest Nicholson Holdings plc. |
−1.5% | |
| 14 Oct 25 | Trading update | Q3 2025 Trading Statement
Q3 revenue grew 6.3% on constant currency basis, strongest quarter since 2021, with both divisions returning to growth. |
+11.6% |
|
in line expectations Q3 2025 Group revenue £405.2m (£395.7m)Q3 2025 Group revenue growth (CCY) +6.3% (-2.0% (Q3 2024))THG Beauty Q3 revenue growth (CCY) +4.2% (+3.2% (Q3 2024))THG Nutrition Q3 revenue growth (CCY) +10.0% (-10.5% (Q3 2024))YTD 2025 Group revenue growth (CCY) +0.3%THG Nutrition customer subscriptions +50% on H1 2025
|
|||
| 10 Oct 25 | Notice of Trading Update
THG to publish trading statement for Q3 2025 on 14 October 2025. |
−1.4% | |
| 19 Sep 25 | Ocean Wilsons
THG promoted to FTSE 250 Index from FTSE SmallCap Index, effective 24 September 2025. |
−3.4% | |
| 11 Sep 25 | Results | Half-year Results
H1 2025 revenue down 2.6% on continuing CCY basis; adjusted EBITDA £24.0m. Q2 momentum continues into Q3 with both divisions expected to return to growth in H2. |
+6.4% |
|
in line with guidance expectations Group revenue £783.4m (£848.1m)Adjusted EBITDA £24.0m (£37.1m)Gross margin 41.1% (42.6%)Net debt £321.4m (£350.5m)Cash and available facilities £279.4mLOOKFANTASTIC loyalty members 3.2m
|
|||
| 10 Sep 25 | Notice of Interim Results
THG to publish interim results for six months ended 30 June 2025 on 11 September 2025. |
+5.8% | |
| 05 Sep 25 | Notification under UKLR 6.4.9R(2)
Senior Independent Director Sue Farr appointed as non-executive director of Vistry Group PLC from 1 October 2025. |
+2.5% | |
| 06 Aug 25 | Disposal, H1 trading and Nutrition update - Amend
THG sells Claremont Ingredients for £103m, delivering 98% return since 2020 acquisition, to reduce net debt. |
+3.7% | |
|
Claremont disposal proceeds c.£103mClaremont original acquisition price £52m (late 2020)Claremont FY 2024 revenue c.£14mClaremont adjusted EBITDA FY 2024 c.£7mH1 2025 adjusted EBITDA c.£24m (£37.1m)Pro forma net debt post-disposal c.£230m
|
|||
| 06 Aug 25 | Disposal, H1 trading and Nutrition update
THG divests Claremont Ingredients for £103m, realising significant return on £52m 2020 acquisition. |
+3.7% | |
|
Claremont disposal proceeds c.£103mClaremont original acquisition cost £52m (late 2020)Claremont FY 2024 revenue c.£14mClaremont adjusted EBITDA FY 2024 c.£7mH1 2025 adjusted EBITDA c.£24m (£37.1m)Pro-forma net debt post-disposal c.£230m
|
|||
| 09 Jul 25 | Changes to Directors’ Responsibilities
Milyae Park appointed to Audit, Risk and Sustainability Committees; Helen Jones designated for workforce engagement. |
+4.8% | |
| 25 Jun 25 | Trading update | AGM Trading Statement
THG returns to revenue growth in Q2 with improvements in Beauty and Nutrition; FY 2025 guidance unchanged. |
+12.8% |
|
Beauty Q2 revenue growth -2.0% to -3.0% (-9.8% in Q1)Nutrition Q2 revenue growth +5.0% to +7.0% (+0.1% in Q1)Myprotein offline doors by end 2025 >40,000 global doorsMyprotein offline units expected 2025 c.45 millionMyprotein offline retail sales value FY 2025 £170mUS Myprotein doors expected by end 2025 c.8,400 (1,500 in 2024)
|
|||
| 30 Apr 25 | Results | Annual Report & Accounts 2024
THG released 2024 Annual Report and Accounts; AGM scheduled for 25 June 2025. |
−2.5% |
| 29 Apr 25 | Results | FY 2024 results and Q1 trading statement
FY 2024 revenue flat, adjusted EBITDA in line with guidance; Q1 2025 revenue down 6.1%, with Nutrition returning to growth. |
−10.7% |
|
in line expectations FY 2024 pre-demerger revenue £1,880.2m (£1,896.7m)FY 2024 adjusted EBITDA £114.4m (£114.1m)Q1 2025 Group continuing revenue £371.4m (£371.4m)THG Beauty FY 2024 revenue £1,108.5m (£1,073.3m)THG Nutrition FY 2024 revenue £579.8m (£657.9m)Net debt £215.3m (£218.2m)
|
|||
| 23 Apr 25 | Response to media speculation
THG rejected unsolicited non-binding proposal from Selkirk to acquire Myprotein for £400m-£600m. |
−1.2% | |
|
Myprotein valuation in proposal £400m - £600m
|
|||
| 04 Apr 25 | Completion of debt refinancing
THG completes debt refinancing, extending maturity to December 2029 and reducing net leverage to 2.2x. |
−4.3% | |
|
Net leverage post-refinancing 2.2x (3.2x)Term Loan B extended €445mTerm Loan A repaid £74mRCF maturity extended May 2029 (May 2026)FY 2024 continuing Adjusted EBITDA £92m
|
|||
| 01 Apr 25 | Equity Raise Post-Transaction Report
THG issued 68.5m shares raising £22.13m for refinancing exercise. |
−2.1% | |
|
Shares issued 68,527,697Proceeds raised £22.13mPlacing price 32.3 penceDiscount to market 5%Percentage of existing shares 5.18%
|
|||
| 27 Mar 25 | Equity Contribution confirmation
THG confirms £90 million equity fundraise with £22 million placing and £68 million convertible loan, admission expected 28 March 2025. |
−3.0% | |
|
Gross proceeds £90 millionMatthew Moulding net commitment £60 millionPlacing proceeds £22 millionConvertible Loan £68 millionPlacing Price 32.3 pencePlacing Shares 68,527,697
|
|||
| 25 Mar 25 | Results | Results of Placing
THG raises £90 million through equity placing and convertible loan, reducing gross leverage via debt repayment. |
+5.5% |
|
Gross proceeds from placing £29.7 millionMatthew Moulding equity contribution £60 millionTotal fundraise £90 millionPlacing price per share 32.3 penceTerm Loan A to be repaid £109 millionTLB reduction €125 million to €475 million
|
|||
| 24 Mar 25 | Fundraise | Proposed debt refinancing and equity placing
THG refinances debt to 2029 with £70m equity raise including £60m from founder Matthew Moulding. |
−7.3% |
|
Equity contribution up to £91.2mMatthew Moulding commitment £60mEUR Term Loan B maturity extension to December 2029Net total leverage post-refinancing 2.6x (3.2x)Continuing Adjusted EBITDA 2024 £92mContinuing revenue FY 2024 £1.7bn
|
|||
| 06 Mar 25 | Inclusion in FTSE 250 Index
THG anticipated for FTSE 250 index inclusion, effective around 21 March 2025. |
+2.0% | |
| 28 Jan 25 | Board change | Appointment of Independent Non-Executive Director
Milyae Park appointed as Independent Non-Executive Director with immediate effect. |
+1.9% |
| 23 Jan 25 | Trading update | Q4 2024 Trading Statement
FY 2024 adjusted EBITDA in-line with expectations; Ingenuity demerger completed; RemainCo targeting mid-single digit revenue growth FY 2025. |
−7.0% |
|
in-line expectations FY 2024 Group continuing revenue £1,879.6m (£1,896.7m)THG Beauty FY 2024 revenue £1,108.3m (£1,073.3m)THG Nutrition FY 2024 revenue £579.6m (£657.9m)Cash and available facilities c. £550mTHG Ingenuity FY 2025 adjusted EBITDA guidance £40m to £45mPotential VAT repayment (4-year retrospective) c. £30m
|
|||
| 08 Jan 25 | Board change | Directorate Change
John Gallemore joined Ingenuity Board as Executive President and resigned from THG board and COO role on demerger completion. |
−2.4% |
| 07 Jan 25 | Director dealing | PDMR/PCA Shareholdings
PDMRs redesignated shares following completion of Ingenuity demerger on 30 December 2024. |
−1.4% |
| 06 Jan 25 | Transfer to ESCC Category
THG's ordinary shares transferred from transition to commercial companies category on FCA Official List. |
+10.8% | |
| 02 Jan 25 | Completion of Demerger
THG completed demerger of Ingenuity; B Shares redesignated as Deferred 1 Shares following distribution to shareholders. |
−3.8% | |
|
Ordinary Shares in issued capital 1,322,058,529Deferred 1 Shares in issued capital 204,404,691
|
|||
| 27 Dec 24 | Result of General Meeting
Shareholders approved B Share redesignation and Ingenuity distribution with 88.71% voting in favour. |
−0.9% | |
|
Votes in favour 836,746,296Votes in favour as % of votes cast 88.71%Votes against 106,496,194Ordinary Shares to be redesignated as B Shares 204,081,632Ingenuity Shares to be distributed 204,081,632Issued share capital represented by votes cast 61.81%
|
|||
| 17 Dec 24 | Ingenuity Shareholders’ Agreement & Articles
THG publishes revised Ingenuity shareholder agreement and articles ahead of January 2025 demerger completion. |
−0.2% | |
| 28 Nov 24 | Ingenuity Demerger Circular and Notice of GM
THG posts circular for shareholder vote on demerging Ingenuity business into independent private company. |
+3.6% | |
| 28 Nov 24 | ESCC transfer effective date, Index eligibility
THG to transfer from transition to ESCC listing category, becoming eligible for FTSE UK Index Series from March 2025. |
+3.6% | |
|
Ordinary Shares in issue 1,525,764,626Transfer effective date 6 January 2025FTSE UK Index Series eligibility March 2025
|
|||
| 27 Nov 24 | Appointment of Corporate Broker
THG appoints Peel Hunt LLP as corporate broker alongside existing brokers Barclays and Jefferies. |
+0.7% | |
| 16 Oct 24 | Director dealing | PDMR/PCA Shareholdings
Matthew Moulding's PCA purchased 20.4m shares at 49p via FIC Shareco Limited. |
+4.8% |
|
Shares purchased 20,408,163Purchase price per share 49pTotal holding after purchase 341,342,346 sharesVoting shares held 219,152,258
|
|||
| 15 Oct 24 | Equity Raise Post-Transaction Report
THG raised £95.4m through issuing 194.7m shares at 49p, representing 14.6% dilution. |
−0.6% | |
|
Gross proceeds £95.4mPlacing Price 49 pence per shareNew Ordinary Shares issued 194,722,333Discount to previous close 5.2%Dilution 14.6% of existing shares
|
|||
| 11 Oct 24 | Results | Results of Placing
THG raises £95.4 million through oversubscribed placing to fund Ingenuity demerger and strengthen balance sheet. |
−7.7% |
|
Gross proceeds raised £95.4 millionPlacing Price 49 pence per shareDiscount to closing price 5.2%New Ordinary Shares issued 194,722,333 sharesMatthew Moulding investment £10 millionFrasers Group investment £10 million
|
|||
| 10 Oct 24 | Fundraise | Launch of Retail Offer
THG launches retail offer of new shares alongside £75m institutional placing, conditional on Ingenuity demerger admission. |
−2.8% |
|
Institutional placing size up to £75mCommitted subscriptions from major shareholders £33mMaximum retail offer size EUR 8mMinimum subscription per retail investor £250
|
|||
| 10 Oct 24 | Fundraise | Update on Ingenuity Demerger and Proposed Placing
THG to raise £75m via placing and subscription to fund Ingenuity demerger into standalone private entity. |
−2.8% |
|
Target equity raise c.£75 millionIngenuityCo board-approved equity valuation up to £100mIngenuity attributed enterprise value up to £307mCommitted investment from Matthew Moulding £10 millionCommitted investment from named shareholders c.£33 million
|
|||
| 10 Oct 24 | Trading update | Q3 2024 Trading Statement
Q3 continuing revenue £433.1m down 0.6% CCY; Beauty and Ingenuity grew, Nutrition declined but improving. |
−2.8% |
|
Q3 2024 continuing revenue £433.1m (-0.6% CCY)THG Beauty revenue £254.7m (+2.8% CCY)THG Nutrition revenue £134.5m (-10.5% CCY)THG Ingenuity external revenue £44.0m (+16.0% CCY)YTD 2024 continuing revenue £1,333.5m (+2.7% CCY)
|
|||
| 17 Sep 24 | Results | Half-year Results
H1 2024 continuing revenue grew 2.2% CCY to £911.1m with record Beauty and Ingenuity EBITDA offset by Nutrition decline. |
−12.4% |
|
towards the lower end of analyst consensus EBITDA range expectations Continuing revenue £911.1m (£910.4m)Continuing adjusted EBITDA £52.3m (£51.5m)THG Beauty revenue £531.0m (£502.5m)THG Beauty adjusted EBITDA £32.6m (£12.1m)THG Nutrition revenue £299.9m (£336.7m)Net debt £350.5m (£268.3m)
|
|||
| 17 Sep 24 | ESCC transfer & Ingenuity demerger update
THG appointed sponsor to transfer to ESCC listing category by March 2025 and exploring Ingenuity demerger. |
−12.4% | |
| 01 Aug 24 | Grant of Share Options
CFO and COO granted nil-cost options over 1.9m shares each, vesting in three years subject to performance targets. |
−2.9% | |
| 24 Jun 24 | Trading update | AGM trading update and Frasers Group partnership
THG reports Q2 revenue growth, confirms FY24 guidance unchanged, and announces multi-year partnership with Frasers Group including Ingenuity agreement and luxury goods disposal. |
+1.5% |
|
THG Beauty app downloads growth YoY +45%Myprotein new branding coverage by end Q3 2024 c.80% of products by online revenueTHG Ingenuity monthly recurring revenue growth June 2024 +30%THG Ingenuity third party revenue growth acceleration Q2 vs Q1Luxury division sales FY 2023 c.£43mLuxury division operating result FY 2023 broadly break-even
|
|||
| 29 Apr 24 | Results | Annual Report & Accounts 2023
Annual Report and Accounts for 2023 published; AGM scheduled for 24 June 2024. |
+2.9% |
| 23 Apr 24 | Trading update | Q1 2024 Trading Statement
Q1 revenue growth accelerated to +4.5% constant currency, driven by THG Beauty's +11.1% growth offsetting Nutrition's -5.8% decline. |
+4.8% |
|
Group revenue (continuing) £455.4m (Q4 2023: +1.1% growth)Group revenue growth (CCY) +4.5% (+1.1%)THG Beauty revenue £267.6m (+2.6%)THG Beauty growth (CCY) +11.1% (Q4 2023: +2.6%)THG Nutrition growth (CCY) -5.8% (Q4 2023: -4.0%)THG Ingenuity external revenue growth (CCY) +5.9% (Q4 2023: -5.4%)
|
|||
| 22 Apr 24 | Notice of Q1 Trading Update
THG will publish Q1 2024 trading update on 23 April 2024 with analyst conference call. |
+3.9% | |
| 10 Apr 24 | Results | Preliminary FY 2023 results
FY 2023 adjusted EBITDA £120.4m, up 48%, free cash flow breakeven achieved, guidance unchanged. |
−11.0% |
|
ahead of January 2024 guidance of above £117.0m expectations Continuing adjusted EBITDA £120.4m (£81.2m)Group adjusted EBITDA £114.1m (£64.1m)Group revenue (continuing) £1,983.7m (£2,048.3m)Gross margin 42.8% (41.3%)Net cash/(debt) (£218.2m) ((£180.6m))Cash and facilities c.£600m
|
|||
| 15 Mar 24 | Board change | Directorate Change
Iain McDonald steps down as Non-Executive Director at end of March 2024 after 14 years. |
−4.8% |
| 13 Mar 24 | Application for Listing and Total Voting Rights
30.6m ordinary shares issued to employee benefit trust, admitted to LSE on 15 March 2024. |
+1.8% | |
| 07 Mar 24 | Grant of Share Options
THG granted nil-cost share options to CFO and COO vesting in 2027 subject to performance targets. |
−1.1% | |
|
Shares awarded to CFO (Damian Sanders) 1,939,788Shares awarded to COO (John Gallemore) 1,745,810Shares to be admitted for employee benefit trust 30,629,135
|
|||
| 04 Mar 24 | Revolving Credit Facility extension to May 2026
RCF extended by 17 months to May 2026; facility reduces to £150m from December 2024. |
−3.2% | |
|
RCF extension to May 2026RCF size from December 2024 £150 millionCurrent RCF £170 millionNet leverage FY 2023 c.1.8x (2.8x FY 2022)Cash and undrawn facilities c.£600 million
|
|||
| 16 Jan 24 | Trading update | Q4 Trading Statement
Q4 revenue returned to growth at 1.1% in constant currency; free cash flow breakeven achieved for FY2023. |
+10.4% |
|
in line with expectations and guidance expectations FY 2023 continuing revenue £1,985.3m (£2,053.3m)Q4 2023 Group revenue growth (CCY) +1.1%FY 2023 Free cash flow breakeven (-£213m)Cash and available facilities c.£600mFY 2023 adjusted EBITDA expected above £117m (c.£67m)Incremental GMV from new partnerships c.£175m
|
|||
| 16 Jan 24 | Ingenuity fulfilment partnership
THG Ingenuity signs three-year fulfilment partnership with Holland & Barrett from Q2 2024, adding £175m incremental GMV. |
+10.4% | |
|
Incremental GMV from new and expanded partnerships c.£175mPartnership duration three yearsStart date Q2 2024
|
|||
| 02 Jan 24 | TVR & 2023 AGM Voting Outcome Update
Iain McDonald steps down from Remuneration Committee following shareholder opposition at 2023 AGM. |
−12.3% | |
|
Total voting rights 1,299,700,302 Ordinary Shares
|
|||
| 05 Dec 23 | Acquisition of Biossance
THG acquires prestige skincare brand Biossance for maximum $20m consideration from Amyris Inc. |
−0.2% | |
|
Maximum consideration $20mBiossance cumulative revenues since 2015 c. $300mGlobal store locations 1,600+Revenue on THG retail sites (12 months) c. $2mAuction date 30 November 2023
|
|||
| 17 Oct 23 | Trading update | Q3 2023 Trading Statement
Q3 revenue declined 4.4% reported (-2.1% constant currency), improving from Q2 with return to growth in September. |
+4.4% |
|
Q3 Group revenue (continuing) £466.5m (-4.4% YoY)Q3 revenue constant currency -2.1% (-6.9% Q2)September revenue constant currency +3.2%LTM free cash generation £5mQ3 THG Beauty £272.0m (-4.4% YoY)Q3 THG Nutrition £156.2m (-4.6% YoY)
|
|||
Company filings. Not investment advice.